Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | VEGFA | P15692 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1340730 | 0.81 | L3MBTL1 (0.72) | L3MBTL1RAB9AMAPTLMNAATM | |
| SCHEMBL2933241 | 0.79 | L3MBTL1 (0.60) | L3MBTL1RAB9AMAPTLMNAATM | |
| SCHEMBL4696880 | 0.78 | TDP1 (0.49) | MAPTLMNANPSR1PPARGCYP2C19 | |
| SCHEMBL4692925 | 0.78 | PPARG (0.54) | PPARGEPAS1VEGFA | |
| SCHEMBL31090839 | 0.77 | L3MBTL1 (0.81) | L3MBTL1RAB9AMAPTLMNAATM | |
| SCHEMBL14681242 | 0.77 | L3MBTL1 (0.81) | L3MBTL1RAB9AMAPTLMNAATM | |
| SCHEMBL8935331 | 0.77 | L3MBTL1 (0.69) | L3MBTL1RAB9AMAPTLMNAATM | |
| SCHEMBL4696071 | 0.76 | GAA (0.49) | MAPTLMNACYP1A2CYP2C19CYP2C9 | |
| SCHEMBL27314240 | 0.76 | TLR8 (0.45) | L3MBTL1PPARG | |
| SCHEMBL3284614 | 0.74 | L3MBTL1 (0.62) | L3MBTL1RAB9AMAPTLMNAATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1053227-B1 | PPAR-GAMMA MODULATORS | AMGEN INC (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20010027200-A1 | PPARgamma modulators | TULARIK INC. | 2001-10-04 | — | — | US | disclosed |
| US-6200995-B1 | PYRIDYLOXYBENZENESULFONAMIDE DERIVATIVES; DIABETES, OBESITY | TULARIK INC. | 2001-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027200-A1 | PPARgamma modulators | PPARG, PPARA, PPARD | L3MBTL1 4080/4885RAB9A 3663/4885MAPT 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.